



BLA 125160/S-281

**SUPPLEMENT APPROVAL**

UCB, Inc.  
Attention: Sandra Bonsall, RAC  
Director, Global Regulatory Affairs  
1950 Lake Park Drive  
Building 2100  
Smyrna, Georgia 30080

Dear Ms. Bonsall:

Please refer to your Supplemental Biologics License Application (sBLA), dated and received April 4, 2017, and your amendments, submitted under section 351(a) of the Public Health Service Act for Cimzia (certolizumab pegol) for injection.

This Prior Approval supplemental biologics application provides for updates to the prescribing information regarding treatment during lactation and pregnancy based on two postmarketing prospective pharmacokinetic studies.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Heather Buck, Regulatory Project Manager, at (301) 796-1413.

Sincerely,

{ See appended electronic signature page }

Joyce Korvick, M.D., M.P.H.  
Deputy Director for Safety  
Division of Gastroenterology and Inborn Errors Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURES: Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
JOYCE A KORVICK  
03/20/2018